WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation
NYSE:WST • US9553061055
Current stock price
293.21 USD
-8.99 (-2.97%)
Last:
This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. WST Profitability Analysis
1.1 Basic Checks
- WST had positive earnings in the past year.
- In the past year WST had a positive cash flow from operations.
- In the past 5 years WST has always been profitable.
- In the past 5 years WST always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 13.21%, WST belongs to the best of the industry, outperforming 96.49% of the companies in the same industry.
- WST has a Return On Equity of 18.15%. This is amongst the best in the industry. WST outperforms 91.23% of its industry peers.
- The Return On Invested Capital of WST (16.07%) is better than 94.74% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for WST is above the industry average of 11.01%.
- The last Return On Invested Capital (16.07%) for WST is above the 3 year average (15.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 18.15% | ||
| ROIC | 16.07% |
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
1.3 Margins
- WST has a better Profit Margin (16.85%) than 84.21% of its industry peers.
- WST's Profit Margin has been stable in the last couple of years.
- WST has a better Operating Margin (21.24%) than 87.72% of its industry peers.
- WST's Operating Margin has been stable in the last couple of years.
- With a Gross Margin value of 36.28%, WST is not doing good in the industry: 61.40% of the companies in the same industry are doing better.
- In the last couple of years the Gross Margin of WST has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.24% | ||
| PM (TTM) | 16.85% | ||
| GM | 36.28% |
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
2. WST Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), WST is creating some value.
- WST has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, WST has less shares outstanding
- WST has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 14.87 indicates that WST is not in any danger for bankruptcy at the moment.
- WST has a Altman-Z score of 14.87. This is amongst the best in the industry. WST outperforms 98.25% of its industry peers.
- WST has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
- The Debt to FCF ratio of WST (0.45) is better than 92.98% of its industry peers.
- A Debt/Equity ratio of 0.07 indicates that WST is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.07, WST is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 14.87 |
ROIC/WACC1.48
WACC10.86%
2.3 Liquidity
- WST has a Current Ratio of 2.71. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
- WST has a Current ratio (2.71) which is in line with its industry peers.
- A Quick Ratio of 2.04 indicates that WST has no problem at all paying its short term obligations.
- WST has a Quick ratio (2.04) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.04 |
3. WST Growth Analysis
3.1 Past
- WST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.03%, which is quite impressive.
- Measured over the past years, WST shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.94% on average per year.
- The Revenue has grown by 11.23% in the past year. This is quite good.
- Measured over the past years, WST shows a small growth in Revenue. The Revenue has been growing by 7.44% on average per year.
EPS 1Y (TTM)20.03%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%46.9%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%21.05%
3.2 Future
- Based on estimates for the next years, WST will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.01% on average per year.
- WST is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.95% yearly.
EPS Next Y11.24%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
EPS Next 5Y9.01%
Revenue Next Year6.04%
Revenue Next 2Y6.13%
Revenue Next 3Y6.47%
Revenue Next 5Y7.95%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. WST Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 36.79 indicates a quite expensive valuation of WST.
- Based on the Price/Earnings ratio, WST is valued a bit cheaper than the industry average as 63.16% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Earnings ratio of 27.15, WST is valued a bit more expensive.
- Based on the Price/Forward Earnings ratio of 32.62, the valuation of WST can be described as expensive.
- Based on the Price/Forward Earnings ratio, WST is valued a bit cheaper than 63.16% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.12. WST is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.79 | ||
| Fwd PE | 32.62 |
4.2 Price Multiples
- WST's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. WST is cheaper than 61.40% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of WST is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 46.15 | ||
| EV/EBITDA | 24.94 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates WST does not grow enough to justify the current Price/Earnings ratio.
- The excellent profitability rating of WST may justify a higher PE ratio.
PEG (NY)3.27
PEG (5Y)4.11
EPS Next 2Y11.04%
EPS Next 3Y11.52%
5. WST Dividend Analysis
5.1 Amount
- WST has a yearly dividend return of 0.33%, which is pretty low.
- Compared to an average industry Dividend Yield of 0.11, WST pays a better dividend. On top of this WST pays more dividend than 84.21% of the companies listed in the same industry.
- With a Dividend Yield of 0.33, WST pays less dividend than the S&P500 average, which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
5.2 History
- The dividend of WST has a limited annual growth rate of 5.48%.
- WST has paid a dividend for at least 10 years, which is a reliable track record.
- WST has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)5.48%
Div Incr Years33
Div Non Decr Years34
5.3 Sustainability
- WST pays out 11.39% of its income as dividend. This is a sustainable payout ratio.
- The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.
DP11.39%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
WST Fundamentals: All Metrics, Ratios and Statistics
NYSE:WST (4/28/2026, 3:05:10 PM)
293.21
-8.99 (-2.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-23 2026-04-23/bmo
Earnings (Next)07-22 2026-07-22/bmo
Inst Owners97.62%
Inst Owner Change-0.55%
Ins Owners0.29%
Ins Owner Change0.38%
Market Cap21.13B
Revenue(TTM)3.22B
Net Income(TTM)542.70M
Analysts80.87
Price Target352.97 (20.38%)
Short Float %3.72%
Short Ratio2.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP11.39%
Div Incr Years33
Div Non Decr Years34
Ex-Date04-29 2026-04-29 (0.22)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18%
Min EPS beat(2)10.24%
Max EPS beat(2)25.77%
EPS beat(4)4
Avg EPS beat(4)18.02%
Min EPS beat(4)10.24%
Max EPS beat(4)25.77%
EPS beat(8)7
Avg EPS beat(8)12.73%
EPS beat(12)11
Avg EPS beat(12)12.39%
EPS beat(16)14
Avg EPS beat(16)12.42%
Revenue beat(2)2
Avg Revenue beat(2)3.79%
Min Revenue beat(2)0.33%
Max Revenue beat(2)7.25%
Revenue beat(4)4
Avg Revenue beat(4)3.25%
Min Revenue beat(4)0.33%
Max Revenue beat(4)7.25%
Revenue beat(8)7
Avg Revenue beat(8)1.68%
Revenue beat(12)8
Avg Revenue beat(12)0.96%
Revenue beat(16)11
Avg Revenue beat(16)0.86%
PT rev (1m)0%
PT rev (3m)-7.08%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)1.61%
EPS NY rev (1m)0.09%
EPS NY rev (3m)3.32%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)2.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.79 | ||
| Fwd PE | 32.62 | ||
| P/S | 6.56 | ||
| P/FCF | 46.15 | ||
| P/OCF | 29.55 | ||
| P/B | 7.07 | ||
| P/tB | 7.35 | ||
| EV/EBITDA | 24.94 |
EPS(TTM)7.97
EY2.72%
EPS(NY)8.99
Fwd EY3.07%
FCF(TTM)6.35
FCFY2.17%
OCF(TTM)9.92
OCFY3.38%
SpS44.69
BVpS41.49
TBVpS39.88
PEG (NY)3.27
PEG (5Y)4.11
Graham Number86.2537 (-70.58%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 18.15% | ||
| ROCE | 19.91% | ||
| ROIC | 16.07% | ||
| ROICexc | 18.95% | ||
| ROICexgc | 19.73% | ||
| OM | 21.24% | ||
| PM (TTM) | 16.85% | ||
| GM | 36.28% | ||
| FCFM | 14.22% |
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.24 | ||
| Cap/Depr | 145.7% | ||
| Cap/Sales | 7.99% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.1% | ||
| Profit Quality | 84.39% | ||
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 14.87 |
F-Score7
WACC10.86%
ROIC/WACC1.48
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)20.03%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%46.9%
EPS Next Y11.24%
EPS Next 2Y11.04%
EPS Next 3Y11.52%
EPS Next 5Y9.01%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%21.05%
Revenue Next Year6.04%
Revenue Next 2Y6.13%
Revenue Next 3Y6.47%
Revenue Next 5Y7.95%
EBIT growth 1Y16.64%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.62%
EBIT Next 3Y20.28%
EBIT Next 5Y16.28%
FCF growth 1Y18.62%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y-5.46%
OCF growth 3Y1.4%
OCF growth 5Y9.82%
WEST PHARMACEUTICAL SERVICES / WST Fundamental Analysis FAQ
What is the fundamental rating for WST stock?
ChartMill assigns a fundamental rating of 7 / 10 to WST.
What is the valuation status for WST stock?
ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.
How profitable is WEST PHARMACEUTICAL SERVICES (WST) stock?
WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 8 / 10.
What is the financial health of WEST PHARMACEUTICAL SERVICES (WST) stock?
The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.
What is the expected EPS growth for WEST PHARMACEUTICAL SERVICES (WST) stock?
The Earnings per Share (EPS) of WEST PHARMACEUTICAL SERVICES (WST) is expected to grow by 11.24% in the next year.